Company profile
Grünenthal GmbH
Privately held: no public share price (Independent, family-owned (Wirtz family) German pharmaceutical company headquartered in Aachen; not publicly traded, not on the roster. Sources: https://clinicaltrials.gov/study/NCT00414349 ; https://api.gleif.org/api/v1/lei-records/529900SH895E31PGLA72 ; https://www.thepharmaletter.com/ones-to-watch/grnenthal ; https://en.wikipedia.org/wiki/Gr%C3%BCnenthal Entity resolved by asset-pipeline-v2.)
Assets
(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Capsaicin (Qutenza)(Qutenza) | Approved | TRPV1 (transient receptor potential vanilloid 1) channelSmall molecule | Diabetic Peripheral Neuropathic Pain |
| Approved | Mu-opioid receptor and norepinephrine transporter (NET)Small molecule | Diabetic Peripheral Neuropathic Pain |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.